Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Estrogen Receptor Positive Breast Cancer 1

Interventions

Cyclophosphamide 39 Rituximab 38 fludarabine 19 Filgrastim 18 Lenalidomide 14 fludarabine phosphate 13 Prednisone 13 Vincristine 12 Peripheral Blood Stem Cell Transplantation 12 Etoposide 12 Doxorubicin 12 Busulfan 12 Radiotherapy 11 Melphalan 11 pembrolizumab 10 Tacrolimus 10 Gemcitabine 9 Methotrexate 8 obinutuzumab 7 Bendamustine Hydrochloride 7 Whole-Body Irradiation 6 Vorinostat 6 Granulocyte Colony-Stimulating Factor 6 Bortezomib 6 Azacitidine 6 Alemtuzumab 6 ibrutinib 5 aldesleukin 5 Mycophenolic Acid 5 Ifosfamide 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡